- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- Doravirine, 2 NRTIs, DOR/3TC/TDF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 4 Weeks to 11 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infection
- Interventions
- DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 25 more
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF, NRTIs, Third Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 40
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
- Conditions
- HIV Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
- Conditions
- HIV-1-infection, Weight Gain
- Interventions
- Doravirine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Houston, Texas
- Conditions
- HIV-1-Infection
- Interventions
- ISL/LEN, Antiretroviral Combinations
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
- Drug
- Lead sponsor
- Quest Clinical Research
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV-1 Infection
- Interventions
- ART, DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more
- Conditions
- HIV-1 Infection
- Interventions
- Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more
- Conditions
- HIV-1 Infection
- Interventions
- MK-8591A
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 13 more
- Conditions
- HIV Infections, Pregnancy Related
- Interventions
- Doravirine
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
- Conditions
- Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
- Interventions
- Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
- Drug
- Lead sponsor
- Walter K. Kraft
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Epigenetic Aging
- Interventions
- Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Houston, Texas
- Conditions
- HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
- Interventions
- Doravirine 100 Mg
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more
- Conditions
- HIV Infections
- Interventions
- Doravirine 100 Mg, Integrase strand transfer inhibitors, Tenofovir alafenamide/emtricitabine, tenofovir disproxil fumarate/emtricitabine
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
- Conditions
- HIV Infection
- Interventions
- DOR/ISL, ART
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 15
- States / cities
- Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more
- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
- Conditions
- Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
- Interventions
- DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
- Drug · Combination Product
- Lead sponsor
- Prism Health North Texas
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
- Conditions
- Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
- Interventions
- Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo
- Drug · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy
- Interventions
- DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Springfield, Missouri